Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals Inc - Asset Resilience Ratio
Enzon Pharmaceuticals Inc (ENZN) has an Asset Resilience Ratio of 18.03% as of June 2013. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2012)
This chart shows how Enzon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Enzon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.00 Million | 18.03% |
| Total Liquid Assets | $3.00 Million | 18.03% |
Asset Resilience Insights
- Good Liquidity Position: Enzon Pharmaceuticals Inc maintains a healthy 18.03% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Enzon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Enzon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Enzon Pharmaceuticals Inc (1999–2012)
The table below shows the annual Asset Resilience Ratio data for Enzon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2012-12-31 | 59.76% | $119.39 Million | $199.78 Million | +42.81pp |
| 2011-12-31 | 16.95% | $58.19 Million | $343.21 Million | +10.58pp |
| 2010-12-31 | 6.38% | $31.17 Million | $488.86 Million | -9.75pp |
| 2009-12-31 | 16.13% | $53.67 Million | $332.75 Million | -2.54pp |
| 2008-12-31 | 18.67% | $65.19 Million | $349.25 Million | -10.81pp |
| 2007-12-31 | 29.48% | $123.91 Million | $420.36 Million | -6.46pp |
| 2006-12-31 | 35.93% | $145.11 Million | $403.83 Million | +19.43pp |
| 2004-12-31 | 16.51% | $107.45 Million | $650.86 Million | +9.48pp |
| 2003-12-31 | 7.02% | $50.74 Million | $722.41 Million | +3.59pp |
| 2002-12-31 | 3.44% | $25.05 Million | $728.57 Million | -8.87pp |
| 2001-12-31 | 12.31% | $75.17 Million | $610.75 Million | -11.26pp |
| 2000-12-31 | 23.56% | $129.52 Million | $549.68 Million | +10.52pp |
| 1999-12-31 | 13.04% | $16.99 Million | $130.25 Million | -- |